Effect of a deslorelin implant in a timed artificial insemination protocol on follicle development, luteal function and reproductive performance of lactating dairy cows.
This study examined the influence of a GnRH agonist containing either 450 or 750 microg of deslorelin in an implant form or a gonadorelin injection (control) to induce ovulation in the Ovsynch protocol on pregnancy rates (PR), embryonic loss, and ovarian function in 593 lactating Holstein cows. Cows were given two injections of PGF2alpha 14 days apart, followed 14 days later by the Ovsynch protocol, and were timed artificially inseminated (TAI) at 68 +/- 3 days postpartum. Blood samples for determination of plasma progesterone concentrations were collected at 24 and 10 days prior to and 11 days after TAI. Pregnancy was diagnosed on Day 27 and reconfirmed on Day 41 after TAI. Non-pregnant, not re-inseminated cows at Day 27 had their ovaries examined by ultrasonography, and the number and size of follicles and presence of luteal tissue were determined. Simultaneously, these cows were re-synchronized with the Ovsynch protocol. Pregnancy during the re-synchronization period was determined between 35 and 41 days after insemination. On Day 27, PR were higher for control (39.0%) and deslorelin 450 microg (DESLORELIN 450) implant (41.3%) than for those receiving the deslorelin 750 microg (DESLORELIN 750) implant (27.5%; P<0.05). Pregnancy losses tended to decrease for DESLORELIN 450 compared with control (5.0% versus 12.7%; P<0.13). Plasma progesterone concentrations did not differ significantly among treatments. Deslorelin suppressed ovarian activity and decreased PR during the re-synchronization period compared with control. The percentage of non-pregnant animals that were re-inseminated by Day 27 was less for deslorelin compared with control. In conclusion, incorporation of an implant of the GnRH agonist deslorelin to induce ovulation in the Ovsynch protocol has the potential to reduce pregnancy losses, but the response was dependent upon implant concentration. Evaluation of lower doses to minimize the negative effects on subsequent fertility is warranted.
Santos
J E P
JE
Veterinary Medicine Teaching and Research Center, University of California-Davis, Tulare, CA 93274, USA. Jsantos@vmtrc.ucdavis.edu
Bartolome
J A
JA
Cerri
R L A
RL
Juchem
S O
SO
Hernandez
O
O
Trigg
T
T
Thatcher
W W
WW
D000034:Abortion, Veterinary / Q000453:epidemiology; D000818:Animals; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000008:administration & dosage; D004343:Drug Implants; D004973:Estrus Synchronization; D005260:Female; D007315:Insemination, Artificial / Q000662:veterinary*; D007774:Lactation; D006080:Ovarian Follicle / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D010053:Ovary / Q000000981:diagnostic imaging; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D012098:Reproduction / Q000187:drug effects*; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D014463:Ultrasonography
D004343:Drug Implants; D017329:Triptorelin Pamoate; D011374:Progesterone; D015237:Dinoprost; C066438:deslorelin